ClinicalTrials.gg
CompletedNCT01736943Updated Feb 24, 2021Results posted

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

A Phase 2 interventional study of Bortezomib and Doxil in Acute Myelogenous Leukemia, sponsored by Joseph Tuscano. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by Joseph Tuscano · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing bortezomib in Leukemia, Myeloid, Acute — none open to participants now, 1 under way, none of them phase 3. Bortezomib · Leukemia, Myeloid, Acute.

Enrollment
17th of 27
25 · median 34
Started
2012
with 1 other
Phase 2
7 of 28
none open now
Registered
22nd of 28
by date
Lead sponsor
1 of 28
Joseph Tuscano

Among the 28 studies testing bortezomib in Leukemia, Myeloid, Acute, this one is the 17th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 22nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 28 studies testing bortezomib in Leukemia, Myeloid, Acute is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing bortezomib in Leukemia, Myeloid, Acute as a file.
02

Study summary

The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.

Read the detailed description

Acute myeloid leukemia (AML) remains largely incurable despite advances that have been made in recent years into increasing the complete response (CR) rates. In elderly patients (over the age of 60), CR rates are lower, 40 to 50%, and long term disease-free and overall survival is less than 10%. The therapeutic options for relapsed/refractory AML are significantly limited. Bortezomib has shown promising activity in patients with advanced hematologic malignancies, including those with leukemia and non-Hodgkin's lymphoma.

Given the available data suggesting efficacy of bortezomib in combination with doxil in patients with relapsed multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and Non Hodgkin's lymphoma (NHL) as well as the known sensitivity of AML to anthracyclines and in vitro data demonstrating the sensitivity of multiply resistant AML cells to bortezomib, we are proposing the use of this combination in patients with relapsed/refractory AML or elderly patients who are not candidates for standard induction therapy.

Using the subcutaneous formulation of bortezomib would provide patients with reduced neurotoxicity and easier schedule due to decreased time in the infusion room and it would decrease overall cost of care.

03

Conditions studied

  • Acute Myelogenous Leukemia

Keywords

  • Bortezomib
  • Doxil
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Female subjects must be either for at least 1 year before the screening visit, is surgically sterilized or if they are of , agree to practice 2 effective methods of from the time of signing the informed consent form through 30 days after the last dose of SQ VELCADE, or agree to completely abstain from heterosexual intercourse.
  • Male subjects, even if surgically sterilized must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.
  • Adults (age 18 to 80) with AML, excluding the M3 subtype, that are not likely to respond to conventional therapy
  • Bone marrow and peripheral blood studies must be available for confirmation of diagnosis.
  • Performance status of 60% or greater by the scale
  • A minimum of 4 weeks must have elapsed since the completion of prior chemotherapy.
  • Patients may have had transplant.
  • There are no minimum hematological parameter requirements prior to the first two cycles, as patients with AML and myelodysplastic syndrome (MDS) are understood to have low (ANC) and counts when the disease is active. However, patients with white blood cell count (WBC) greater than 30,000 will receive hydroxyurea to reduce the WBC count to below 30,000 at which point they may begin treatment.
  • A pretreatment calculated (absolute value) of ≥ 40 ml/minute or serum creatinine of \< 1.5 x is required.
  • Patients must have a serum ≤1.5 mg/dl, serum glutamic-oxaloacetic transaminase () and serum glutamic-pyruvic transaminase (SGPT) ≤2.5 times the institutional upper limits of normal.

Exclusion criteria

Exclusion Criteria:

  • There is no specific and that will exclude patients from this study given the natural history of AML.
  • Patient has greater than or equal to Grade 2 peripheral neuropathy
  • Patient had myocardial infarction within 6 months prior to enrollment or has Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at screening must be documented by the investigator as not medically relevant. An (LVEF) must be > 50
  • Patient has to VELCADE, boron, or mannitol.
  • Female subject is pregnant or lactating.
  • Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on Day 1 before first dose of study drug, if applicable.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Diagnosed or treated for another within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  • Participation in clinical trials with other agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
  • Radiation therapy within 3 weeks before randomization. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.
  • Patients with active/uncontrolled central nervous system (CNS) leukemia
  • Patients eligible, at the time of starting treatment, for curative therapeutic approaches (such as transplant) are not eligible for the trial.
  • Patients may not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study other than hydroxyurea for control of counts.
  • (HIV)-positive.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Bortezomib + Doxil

    Bortezomib will be given subcutaneously at 1.5mg/m2 on days 1, 4, 8 and 11 of a 3 week cycle. Doxil will be administered once every three weeks as a single intravenous infusion at a dose of 40 mg/m2 (day 4 of each cycle).

    Drug: Bortezomib · Drug: Doxil

Interventions

  • Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.

    Also known as: Velcade

  • DrugLiposomal doxorubicinStudies of Liposomal doxorubicinLiposomal doxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.

    Also known as: LipoDox; pegylated liposomal doxorubicin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    The time from first day of treatment to the first observation of disease progression or death due to any cause. If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up.

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall Survival

    Overall survival wil be measured as the time from start of treatment to the Date of death or the last date the patient was known to be alive

    Time frame: Up to two years

  2. Toxicity Information Recorded Will Include the Type, Severity, Time of Onset, Time of Resolution, and the Probable Association With the Study Regimen.

    Toxicity will be evaluated based on the standard NCI Common Toxicity Criteria for Adverse Effects CTCAE) V.4.0 grading criteria.

    Time frame: Up to two years

07

Results

Posted Feb 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneBortezomib + Doxil
Started25
Completed25
Not completed0

Outcome measures

PrimaryProgression Free Survival

The time from first day of treatment to the first observation of disease progression or death due to any cause. If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up.

Time frame:
Up to 2 years
Reported as:
Median · days
Progression Free Survival
daysBortezomib + Doxil
Progression Free Survival21 (17 to NA)
SecondaryOverall Survival

Overall survival wil be measured as the time from start of treatment to the Date of death or the last date the patient was known to be alive

Time frame:
Up to two years
Reported as:
Median · Days
Overall Survival
DaysBortezomib + Doxil
Overall Survival50 (41 to NA)
SecondaryToxicity Information Recorded Will Include the Type, Severity, Time of Onset, Time of Resolution, and the Probable Association With the Study Regimen.

Toxicity will be evaluated based on the standard NCI Common Toxicity Criteria for Adverse Effects CTCAE) V.4.0 grading criteria.

Time frame:
Up to two years
Reported as:
Number · participants
Toxicity Information Recorded Will Include the Type, Severity, Time of Onset, Time of Resolution, and the Probable Association With the Study Regimen.
participantsBortezomib + Doxil
Abdominal pain4
Alanine aminotransferase increased3
Anemia17
Anorexia7
Aspartate aminotransferase increased4
Chills4
Constipation4
Cough4
Diarrhea9
Dizziness8
Dyspnea10
Edema limbs3
Epitaxis4
Fatigue15
Febrile neutopenia12
Gastrointestinal disorders - Other, gum tenderness3
Generalized muscle weakness4
Headache5
Hypoalbuminemia6
Hypocalcemia4
Hypokalemia3
Hyponatremia7
Hypotension4
Infections and infestations - Other, bacteremia3
Insomnia4
Lymphocyte count decreased12
Malaise4
Mucositis oral4
Nausea15
Neutrophil count decreased10
Peripheral sensory neuropathy4
Platelet count decreased18
Respiratory, thoracic and mediastinal disorders - Other, tachypnea3
Skin and subcutaneous tissue disorders - Other, Ecchymoses4
Vomiting8
White blood cell decreased14

Adverse events

Collected over Up to 30 days after discontinuation of study drugs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib + Doxil1/25 (4%)10/25 (40%)18/25 (72%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBortezomib + Doxil
Atrial fibrillationCardiac disorders1/25
Back painMusculoskeletal and connective tissue disorders1/25
Bronchial infectionInfections and infestations1/25
bronchopulmonary hemorrhageRespiratory, thoracic and mediastinal disorders1/25
Catheter related infectionInfections and infestations1/25
Febrile neutropeniaBlood and lymphatic system disorders1/25
FractureInjury, poisoning and procedural complications1/25
Heart failureCardiac disorders1/25
Infections and infestations - Other, BacteremiaInfections and infestations1/25
neoplasms benign, malignant and unspecified (incl cysts and polyps) - other, specifyNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/25
Most frequent other events
Showing 10 of 59
Most frequent other events
EventBortezomib + Doxil
Platelet count decreasedInvestigations18/25
AnemiaBlood and lymphatic system disorders17/25
FatigueGeneral disorders15/25
NauseaGastrointestinal disorders15/25
White blood cell decreasedInvestigations14/25
Febrile neutropeniaBlood and lymphatic system disorders12/25
Lymphocyte count decreasedInvestigations12/25
DyspneaRespiratory, thoracic and mediastinal disorders10/25
neutrophil count decreasedInvestigations10/25
DiarrheaGastrointestinal disorders9/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bortezomib + Doxil
<=18 years0
Between 18 and 65 years14
>=65 years11
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib + Doxil
Female12
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bortezomib + Doxil
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White20
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Bortezomib + Doxil
United States25
08

Study locations

1 site
  • University of California Comprehensive Cancer Center
    Sacramento, California 95817, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in May 2019, 77 months.

Results were first posted in Feb 2021, 1 year 9 months after primary completion.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 77 months is above that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Nov 29, 2012
StartActual
Dec 19, 2012
Primary completionActual
May 20, 2019
CompletionActual
May 20, 2019
Results first posted
Feb 24, 2021
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01736943
Lead sponsor
Joseph Tuscano
Responsible party
Joseph Tuscano (Principal Investigator, University of California, Davis) — Sponsor-investigator
First posted
Nov 29, 2012
Start date
Dec 19, 2012
Primary completion
May 20, 2019
Completion
May 20, 2019
Results posted
Feb 24, 2021
Last update
Feb 24, 2021

Study contacts

Joseph Tuscano, MD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Liposomal doxorubicin

Start the discussion